Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McGill University

$27,000.00

Evaluating Novel Therapeutic Approaches for NRAS Mutant Melanoma

EF 2025-26

Résumé
Metastatic melanoma is a fatal cancer. Around 20-30% of cutaneous melanomas are driven by an NRAS gene mutation. Immune Checkpoint Inhibitors (ICI) have improved survival rates for melanoma but NRAS mutant melanoma is associated with resistance. NRAS-mutant tumors may resist ICI through inhibiting anti-cancer immune signals. Our lab has investigated immune-related effectors associated with NRAS and identified LNK (SH2B3), an adaptor protein. LNK is known to inhibit interferon-gamma signalling, which T cells use to promote cancer-cell death. Therefore, LNK could be allowing NRAS mutant melanoma to survive immune attack. Our project uses the breakthrough pan-RAS inhibitor, RMC-7977, to investigate the relationship between NRAS-inhibition and LNK. We hypothesize that RMC-797 will suppress NRAS and LNK expression and restoring tumor sensitivity to interferon gamma. We will focus on three goals: Evaluate RMC-7977 in melanoma models: We will confirm how RMC-7977 blocks cancer growth signals and suppresses LNK across different mutational subtypes of melanoma, ensuring its is specific to NRAS mutations. Evaluate the role of LNK: Using genetically engineered melanoma cells where LNK is either knocked out or overexpressed, we will determine if LNK is a key factor that causes tumors to limit interferon gamma signalling and as well as the efficacy of RMC-7977. Evaluate New Strategies in Vivo: We will test whether LNK knockout makes the tumors significantly more sensitive to RMC-7977 in animal models. This project defines LNK as a new target for NRAS mutant melanoma, potentially allowing us to re-sensitize tumors to immune signaling and enhancing the therapeutic effect of RMC-7977. This work could provide a much-needed precision therapy for patients with this aggressive cancer.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572980
Name
Vrkoc Meghan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating Novel Therapeutic Approaches for NRAS Mutant Melanoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Akt Signalling; Antitumor Immunity; Cytokine Signalling; Ifn / Jak-Stat Pathway; Immune Checkpoint Inhibitor (Ici) Resistance; Lnk (Sh2b3); Mapk Signalling; Nras-Mutant Melanoma; Rmc-7977; Tumor Immune Microenvironment (Time)
Abstract
Metastatic melanoma is a fatal cancer. Around 20-30% of cutaneous melanomas are driven by an NRAS gene mutation. Immune Checkpoint Inhibitors (ICI) have improved survival rates for melanoma but NRAS mutant melanoma is associated with resistance. NRAS-mutant tumors may resist ICI through inhibiting anti-cancer immune signals. Our lab has investigated immune-related effectors associated with NRAS and identified LNK (SH2B3), an adaptor protein. LNK is known to inhibit interferon-gamma signalling, which T cells use to promote cancer-cell death. Therefore, LNK could be allowing NRAS mutant melanoma to survive immune attack. Our project uses the breakthrough pan-RAS inhibitor, RMC-7977, to investigate the relationship between NRAS-inhibition and LNK. We hypothesize that RMC-797 will suppress NRAS and LNK expression and restoring tumor sensitivity to interferon gamma. We will focus on three goals: Evaluate RMC-7977 in melanoma models: We will confirm how RMC-7977 blocks cancer growth signals and suppresses LNK across different mutational subtypes of melanoma, ensuring its is specific to NRAS mutations. Evaluate the role of LNK: Using genetically engineered melanoma cells where LNK is either knocked out or overexpressed, we will determine if LNK is a key factor that causes tumors to limit interferon gamma signalling and as well as the efficacy of RMC-7977. Evaluate New Strategies in Vivo: We will test whether LNK knockout makes the tumors significantly more sensitive to RMC-7977 in animal models. This project defines LNK as a new target for NRAS mutant melanoma, potentially allowing us to re-sensitize tumors to immune signaling and enhancing the therapeutic effect of RMC-7977. This work could provide a much-needed precision therapy for patients with this aggressive cancer.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vrkoc, Meghan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~